REG - OptiBiotix Health - Launch of SlimBiome in leading US brand

OptiBiotix HealthAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250814:nRSN2309Va&default-theme=true

RNS Number : 2309V  OptiBiotix Health PLC  14 August 2025

14 August 2025

 

OptiBiotix Health plc

("OptiBiotix" or the "Company")

 

Launch of SlimBiome® in leading US brand

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing
products which reduce hunger and food cravings, enhance the gut microbiome,
and sweet fibres as healthy sugar substitutes announces the launch of a
product containing its award-winning appetite reducing SlimBiome® in
Hydroxycut, which markets itself as the No. 1 selling weight loss supplement
brand in the United States of America ("USA").

 

This announcement confirms the launch of the first product under the brand
name 'Hydroxycut Hunger Control', and follows on from the first order
announcement on 15 April
(https://www.optibiotix-ir.com/content/news/archive/2025/150425)
(https://www.optibiotix-ir.com/content/news/archive/2025/150425) 2025
(https://www.optibiotix-ir.com/content/news/archive/2025/150425) . The product
is sold through online outlets and retail outlets such as Walmart (as shown
here
(https://www.walmart.com/ip/Hydroxycut-Hunger-Control-Drink-Mix-Tropical-Peach/16531301315?classType=REGULAR)
), and product marketing includes two studies carried out by OptiBiotix which
demonstrate reduction in hunger of 74% and 83%.  Orders for a second product
application have been received and expected to be launched later this year.

 

Hydroxycut is America's No.1 selling weight loss supplement brand and has sold
over 100 million bottles of its product over the last two decades*. Hydroxycut
products are sold online and via major retail outlets across the USA such as
Walmart, Kroger, Target, GNC, Kmart, Albertsons, CVS Pharmacies and more. The
brand has high customer awareness and in recent years has become increasingly
known for its science backed products. The introduction of SlimBiome®, with
its scientifically substantiated health claims of hunger control, helps to
differentiate these products from other weight management products on the
market.

 

This news is significant for the Company as it represents the inclusion of
SlimBiome® in the products of one of the USA's most popular weight management
brands which has led to orders totalling just under five metric tonnes for
SlimBiome® in 2025. The Board believes that the opportunity has potential for
future development and will provide further updates in due course.

 

Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to announce the
launch of products containing our patented award winning SlimBiome® in the
USA. The Company has been working with Hydroxycut for almost two years to
carry out human studies which allows the brand to make health claims of
reductions in hunger of 74% and 83% in the USA. The launch with Hydroxycut
substantiates the science behind SlimBiome and helps build the SlimBiome brand
in consumer markets around the world. This is another example of the Company
launching products with well-known brands in key international markets which
if successful, individually and collectively, have the potential to make a
significant contribution to future sales growth and shareholder value."

 

* Hydroxycut: America's Best Selling Weight Loss Supplement
(https://www.hydroxycut.com/?srsltid=AfmBOophDnO_kVD9oQl4v1Ne01Z_WDOXN7N9_d-A8t9idJNzno5eS3lK)

 

The Directors of the Company are responsible for the release of this
announcement.

 

For further information, please contact:

 

 For further information, please contact: OptiBiotix Health plc      www.optibiotix.com (http://www.optibiotix.com/)
 Neil Davidson, Chairman           Contact via Walbrook below
 Stephen O'Hara, Chief Executive

 Cairn Financial Advisers LLP (NOMAD and Broker)                     Tel: 020 7213 0880
 Liam Murray / Jo Turner / Ludovico Lazzaretti

 Walbrook PR Ltd                                                     Mob: 07876 741 001
 Anna Dunphy

 

About OptiBiotix - www.optibiotix.com (http://www.optibiotix.com/)

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings
science to the development of compounds which modify the human microbiome -
the collective genome of the microbes in the body - in order to prevent and
manage human disease and promote wellness.

 

OptiBiotix has an extensive R&D programme working with leading academics
in the development of microbial strains, compounds, and formulations which are
used as active ingredients and supplements. More than twenty international
food and healthcare supplement companies have signed agreements with
OptiBiotix to incorporate their human microbiome modulators into a wide range
of food products and drinks.

 

OptiBiotix is also developing its own range of consumer supplements and health
products. The Company's current areas of focus include obesity, cardiovascular
health, and diabetes.

 

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward
looking statements. Forward looking statements are identified by their use of
terms and phrases such as ''believe'', ''could'', "should" ''envisage'',
''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect",
''will'' or the negative of those, variations or comparable expressions,
including references to assumptions.  These forward looking statements are
not based on historical facts but rather on the Directors' current
expectations and assumptions regarding the Company's future growth, results of
operations, performance, future capital and other expenditures (including the
amount, nature and sources of funding thereof), competitive advantages,
business prospects and opportunities. Such forward looking statements reflect
the Directors' current beliefs and assumptions and are based on information
currently available to the Directors.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  PRLGZGMRKFLGKZM